{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:54:13Z","timestamp":1793969653170,"version":"4.8.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-026-01396-x","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:25:06Z","timestamp":1773505506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting"],"prefix":"10.1186","volume":"16","author":[{"given":"Emirhan","family":"Harbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokce Belge","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse T.","family":"Kendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Muniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Lucien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadel A.","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"1396_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"1396_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63\u201389. https:\/\/doi.org\/10.14740\/wjon1191.","journal-title":"World J Oncol"},{"key":"1396_CR3","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3390\/curroncol30020178","volume":"30","author":"CV Berenguer","year":"2023","unstructured":"Berenguer CV, Pereira F, C\u00e2mara JS, Pereira JAM. Underlying features of prostate cancer\u2014statistics, risk factors, and emerging methods for its diagnosis. Curr Oncol. 2023;30:2300\u201321. https:\/\/doi.org\/10.3390\/curroncol30020178.","journal-title":"Curr Oncol"},{"key":"1396_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15205047","volume":"15","author":"TK Le","year":"2023","unstructured":"Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L, et al. Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments. Cancers. 2023;15:5047. https:\/\/doi.org\/10.3390\/cancers15205047.","journal-title":"Cancers"},{"key":"1396_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","volume":"82","author":"DG Tang","year":"2022","unstructured":"Tang DG. Understanding and targeting prostate cancer cell heterogeneity and plasticity. Semin Cancer Biol. 2022;82:68\u201393. https:\/\/doi.org\/10.1016\/j.semcancer.2021.11.001.","journal-title":"Semin Cancer Biol"},{"key":"1396_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6030082","volume":"6","author":"U Testa","year":"2019","unstructured":"Testa U, Castelli G, Pelosi E. Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications. Medicines. 2019;6:82. https:\/\/doi.org\/10.3390\/medicines6030082.","journal-title":"Medicines"},{"key":"1396_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther. 2024;9:170. https:\/\/doi.org\/10.1038\/s41392-024-01851-y.","journal-title":"Signal Transduct Target Ther"},{"key":"1396_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1042\/EBC20220025","volume":"66","author":"Q Yan","year":"2022","unstructured":"Yan Q, Fang X, Li C, Lan P, Guan X. Oncofetal proteins and cancer stem cells. Essays Biochem. 2022;66:423\u201333. https:\/\/doi.org\/10.1042\/EBC20220025.","journal-title":"Essays Biochem"},{"key":"1396_CR9","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.3390\/ijms20225752","volume":"20","author":"HL Tan","year":"2019","unstructured":"Tan HL, Choo A. Opportunities for antibody discovery using human pluripotent stem cells: conservation of oncofetal targets. Int J Mol Sci. 2019;20:5752. https:\/\/doi.org\/10.3390\/ijms20225752.","journal-title":"Int J Mol Sci"},{"key":"1396_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-023-09445-6","volume":"20","author":"K Garapati","year":"2023","unstructured":"Garapati K, Ding H, Charlesworth MC, Kim Y, Zenka R, Saraswat M, et al. sBioSITe enables sensitive identification of the cell surface proteome through direct enrichment of biotinylated peptides. Clin Proteomics. 2023;20:56. https:\/\/doi.org\/10.1186\/s12014-023-09445-6.","journal-title":"Clin Proteomics"},{"key":"1396_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00262-016-1917-3","volume":"66","author":"PL Stern","year":"2017","unstructured":"Stern PL, Harrop R. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. Cancer Immunol Immunother. 2017;66:415\u201326. https:\/\/doi.org\/10.1007\/s00262-016-1917-3.","journal-title":"Cancer Immunol Immunother"},{"key":"1396_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41568-022-00497-8","volume":"22","author":"A Sharma","year":"2022","unstructured":"Sharma A, Bl\u00e9riot C, Currenti J, Ginhoux F. Oncofetal reprogramming in tumour development and progression. Nat Rev Cancer. 2022;22:593\u2013602. https:\/\/doi.org\/10.1038\/s41568-022-00497-8.","journal-title":"Nat Rev Cancer"},{"key":"1396_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/00007890-196301020-00004","volume":"1","author":"GI Abelev","year":"1963","unstructured":"Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS. PRODUCTION OF EMBRYONAL \u03b1-GLOBULIN BY TRANSPLANTABLE MOUSE HEPATOMAS. Transplantation. 1963;1:174\u201380. https:\/\/doi.org\/10.1097\/00007890-196301020-00004.","journal-title":"Transplantation"},{"key":"1396_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1084\/jem.122.3.467","volume":"122","author":"P Gold","year":"1965","unstructured":"Gold P, Freedman SO. SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM. J Exp Med. 1965;122:467\u201381. https:\/\/doi.org\/10.1084\/jem.122.3.467.","journal-title":"J Exp Med"},{"key":"1396_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/200995a0","volume":"200","author":"F Schapira","year":"1963","unstructured":"Schapira F, Dreyfus J-C, Schapira G. Anomaly of aldolase in primary liver cancer. Nature. 1963;200:995\u20137. https:\/\/doi.org\/10.1038\/200995a0.","journal-title":"Nature"},{"key":"1396_CR16","first-page":"261","volume":"13","author":"HT Wepsic","year":"1983","unstructured":"Wepsic HT. Overview of oncofetal antigens in cancer. Ann Clin Lab Sci. 1983;13:261\u20136.","journal-title":"Ann Clin Lab Sci"},{"key":"1396_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.14740\/wjon1425","volume":"14","author":"S Desai","year":"2023","unstructured":"Desai S, Guddati AK. Carcinoembryonic antigen, carbohydrate antigen 19\u2009\u2212\u20099, cancer antigen 125, prostate-specific antigen and other cancer markers: a primer on commonly used cancer markers. World J Oncol. 2023;14:4\u201314. https:\/\/doi.org\/10.14740\/wjon1425.","journal-title":"World J Oncol"},{"key":"1396_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162601","volume":"11","author":"S Moein","year":"2022","unstructured":"Moein S, Tenen DG, Amabile G, Chai L. SALL4: an intriguing therapeutic target in cancer treatment. Cells. 2022;11:2601. https:\/\/doi.org\/10.3390\/cells11162601.","journal-title":"Cells"},{"key":"1396_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042053","volume":"23","author":"B Sun","year":"2022","unstructured":"Sun B, Xu L, Bi W, Ou W-B. SALL4 oncogenic function in cancers: mechanisms and therapeutic relevance. Int J Mol Sci. 2022;23:2053. https:\/\/doi.org\/10.3390\/ijms23042053.","journal-title":"Int J Mol Sci"},{"key":"1396_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.62","author":"J Talukdar","year":"2023","unstructured":"Talukdar J, Srivastava TP, Sahoo OS, Karmakar A, Rai AK, Sarma A, et al. Cancer stem cells: signaling pathways and therapeutic targeting. MedComm \u2013 Oncology. 2023. https:\/\/doi.org\/10.1002\/mog2.62.","journal-title":"MedComm \u2013 Oncology"},{"key":"1396_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50215-z","volume":"14","author":"S Liu","year":"2024","unstructured":"Liu S, Hawley SJ, Kunder CA, Hsu E-C, Shen M, Westphalen L, et al. High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. Sci Rep. 2024;14:486. https:\/\/doi.org\/10.1038\/s41598-023-50215-z.","journal-title":"Sci Rep"},{"key":"1396_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/bjc.1990.20","volume":"61","author":"P Southall","year":"1990","unstructured":"Southall P, Boxer G, Bagshawe K, Hole N, Bromley M, Stern P. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61:89\u201395. https:\/\/doi.org\/10.1038\/bjc.1990.20.","journal-title":"Br J Cancer"},{"key":"1396_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2014.07.004","volume":"29","author":"PL Stern","year":"2014","unstructured":"Stern PL, Brazzatti J, Sawan S, McGinn OJ. Understanding and exploiting 5T4 oncofoetal glycoprotein expression. Semin Cancer Biol. 2014;29:13\u201320. https:\/\/doi.org\/10.1016\/j.semcancer.2014.07.004.","journal-title":"Semin Cancer Biol"},{"key":"1396_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/bjc.1994.173","volume":"69","author":"T Starzynska","year":"1994","unstructured":"Starzynska T, Marsh P, Schofield P, Roberts S, Myers K, Stern P. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994;69:899\u2013902. https:\/\/doi.org\/10.1038\/bjc.1994.173.","journal-title":"Br J Cancer"},{"key":"1396_CR25","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00259-024-06941-1","volume":"52","author":"Y He","year":"2025","unstructured":"He Y, Tian R, Xu D, Wu Y, Rina S, Chen T, et al. Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen. Eur J Nucl Med Mol Imaging. 2025;52:611\u201322. https:\/\/doi.org\/10.1007\/s00259-024-06941-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1396_CR26","unstructured":"Li D, Wang Q, Zhu M, Wan Y, Yang Z. Hua Zhu. In vivo PET imaging of 5T4 positive tumor cells using 89Zr-DFO-MY9. J Nucl Med. 2024.65 (supplement 2) 242487."},{"key":"1396_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11523-019-00650-8","volume":"14","author":"YL Wan","year":"2019","unstructured":"Wan YL, Sapra P, Bolton J, Chua JX, Durrant LG, Stern PL. Combination treatment with an antibody\u2013drug conjugate (A1mcMMAF) targeting the oncofetal glycoprotein 5T4 and carboplatin improves survival in a xenograft model of ovarian cancer. Target Oncol. 2019;14:465\u201377. https:\/\/doi.org\/10.1007\/s11523-019-00650-8.","journal-title":"Target Oncol"},{"key":"1396_CR28","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1158\/1535-7163.MCT-20-0565","volume":"20","author":"RA Smith","year":"2021","unstructured":"Smith RA, Zammit DJ, Damle NK, Usansky H, Reddy SP, Lin J-H, et al. ASN004, a 5T4-targeting scFv-Fc antibody\u2013drug conjugate with high drug-to-antibody ratio, induces complete and durable tumor regressions in preclinical models. Mol Cancer Ther. 2021;20:1327\u201337. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0565.","journal-title":"Mol Cancer Ther"},{"key":"1396_CR29","doi-asserted-by":"publisher","unstructured":"Sen S, Sahota S, Siu LL, Marron TU, Haddox CL, LoRusso P, et al. TUB-030, a novel ADC targeting 5T4: A phase I\/IIa multi-center, first-in-human clinical trial (5-STAR 1\u201301) in patients with advanced solid tumors. J Clin Oncol. 2025;43. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS3164.","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3164"},{"key":"1396_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10637-016-0419-7","volume":"35","author":"GI Shapiro","year":"2017","unstructured":"Shapiro GI, Vaishampayan UN, LoRusso P, Barton J, Hua S, Reich SD, et al. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs. 2017;35:315\u201323. https:\/\/doi.org\/10.1007\/s10637-016-0419-7.","journal-title":"Invest New Drugs"},{"key":"1396_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2014","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/ therapeutic implications. Genes Cancer. 2014;6:84\u2013105. https:\/\/doi.org\/10.18632\/genesandcancer.40.","journal-title":"Genes Cancer"},{"key":"1396_CR32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.11648\/j.ajcem.20210903.14","volume":"9","author":"M Shen","year":"2021","unstructured":"Shen M, Liu S, Stoyanova T. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. Am J Clin Exp Urol. 2021;9:73\u201387.","journal-title":"Am J Clin Exp Urol"},{"key":"1396_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI185408","author":"H Chen","year":"2025","unstructured":"Chen H, Zhao L, Pang Y, Shi J, Gao H, Sun Y, et al. 68Ga-MY6349 PET\/CT imaging to assess Trop2 expression in multiple types of cancer. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/JCI185408.","journal-title":"J Clin Invest"},{"key":"1396_CR34","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1007\/s00259-025-07326-8","volume":"52","author":"D Jiang","year":"2025","unstructured":"Jiang D, Chu Z, Wu Y, Zhang Y, Liu Y, Ge Q, et al. [68Ga]Ga-NOTA-T4 immunoPET imaging for evaluating TROP2 expression in patients with solid tumors. Eur J Nucl Med Mol Imaging. 2025;52:4547\u201357. https:\/\/doi.org\/10.1007\/s00259-025-07326-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1396_CR35","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s44321-024-00059-5","volume":"16","author":"W Huang","year":"2024","unstructured":"Huang W, Zhang Y, Cao M, Wu Y, Jiao F, Chu Z, et al. ImmunoPET imaging of Trop2 in patients with solid tumours. EMBO Mol Med. 2024;16:1143\u201361. https:\/\/doi.org\/10.1038\/s44321-024-00059-5.","journal-title":"EMBO Mol Med"},{"key":"1396_CR36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00259-021-05563-1","volume":"49","author":"W Chen","year":"2022","unstructured":"Chen W, Li M, Younis MH, Barnhart TE, Jiang D, Sun T, et al. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:861\u201370. https:\/\/doi.org\/10.1007\/s00259-021-05563-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1396_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s44276-024-00106-1","volume":"2","author":"R Sultana","year":"2024","unstructured":"Sultana R, Chen S, Lim EH, Dent R, Chowbay B. Efficacy and safety of sacituzumab Govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis. BJC Rep. 2024;2:85. https:\/\/doi.org\/10.1038\/s44276-024-00106-1.","journal-title":"BJC Rep"},{"key":"1396_CR38","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","volume":"43","author":"J Sands","year":"2025","unstructured":"Sands J, Ahn M-J, Lisberg A, Cho BC, Blumenschein G, Shum E, et al. Datopotamab Deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol. 2025;43:1254\u201365. https:\/\/doi.org\/10.1200\/JCO-24-01349.","journal-title":"J Clin Oncol"},{"key":"1396_CR39","doi-asserted-by":"publisher","first-page":"P6-20-16","DOI":"10.1158\/1538-7445.SABCS18-P6-20-16","volume":"79","author":"W Tang","year":"2019","unstructured":"Tang W, Huang X, Ou Z, Yan H, Gan J, Dong Q, et al. Abstract P6-20-16: BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of triple negative breast cancer. Cancer Res. 2019;79:P6-20-16-P6-20-16. https:\/\/doi.org\/10.1158\/1538-7445.SABCS18-P6-20-16.","journal-title":"Cancer Res"},{"key":"1396_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/path.6063","volume":"260","author":"W Butler","year":"2023","unstructured":"Butler W, Xu L, Zhou Y, Cheng Q, Hauck JS, He Y, et al. Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer. J Pathol. 2023;260:43\u201355. https:\/\/doi.org\/10.1002\/path.6063.","journal-title":"J Pathol"},{"key":"1396_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","volume":"65","author":"GK Abou-Alfa","year":"2016","unstructured":"Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park J-W, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016;65:289\u201395. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.004.","journal-title":"J Hepatol"},{"key":"1396_CR42","doi-asserted-by":"publisher","unstructured":"Heczey A, Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney A et al. Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers. 2024. https:\/\/doi.org\/10.21203\/rs.3.rs-4103623\/v1","DOI":"10.21203\/rs.3.rs-4103623\/v1"},{"key":"1396_CR43","first-page":"2459","volume":"63","author":"Q Chen","year":"2022","unstructured":"Chen Q, Zhou X, Van Juno V, Conti P, Chen K. Developing a new 18F-labeled peptide for PET imaging of GPC3 expression in hepatocellular carcinoma. J Nucl Med. 2022;63:2459.","journal-title":"J Nucl Med"},{"key":"1396_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11307-019-01356-z","volume":"22","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang J, Gu J, Hu K, Huang S, Conti PS, et al. Radiofluorinated GPC3-binding peptides for PET imaging of hepatocellular carcinoma. Mol Imaging Biol. 2020;22:134\u201343. https:\/\/doi.org\/10.1007\/s11307-019-01356-z.","journal-title":"Mol Imaging Biol"},{"key":"1396_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107352","volume":"147","author":"C Mo","year":"2024","unstructured":"Mo C, Sun P, Liang H, Chen Z, Wang M, Fu L, et al. Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor. Bioorg Chem. 2024;147:107352. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107352.","journal-title":"Bioorg Chem"},{"key":"1396_CR46","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1021\/acsptsci.4c00504","volume":"7","author":"Z Li","year":"2024","unstructured":"Li Z, Mo C, Li C, Wang Q, Huang S, Huang Y, et al. Gallium-68 labeled positron emission computed tomography tracer targeting Glypican-3 with high contrast for hepatocellular carcinoma imaging. ACS Pharmacol Transl Sci. 2024;7:4021\u201331. https:\/\/doi.org\/10.1021\/acsptsci.4c00504.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1396_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ph18111656","volume":"18","author":"E-M Burger","year":"2025","unstructured":"Burger E-M, Hill C, Wodtke R, Zarschler K, Laube M, Donat CK, et al. In vitro characterization of the published Glypican-3-targeting peptide TJ12P2 reveals a lack of specificity and potency. Pharmaceuticals. 2025;18:1656. https:\/\/doi.org\/10.3390\/ph18111656.","journal-title":"Pharmaceuticals"},{"key":"1396_CR48","unstructured":"Fanching Lin R, Clift K, Salvador M, Guest D, Kim S, Horton et al. Novel GPC3-targeted radiopharmaceutical therapy for hepatocellular carcinoma and prostate cancer: preclinical characterization in rodents and non-human primates. J Nucl Med. 2024.65 (supplement 2) 241022."},{"key":"1396_CR49","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2967\/jnumed.123.266766","volume":"65","author":"F Lin","year":"2024","unstructured":"Lin F, Clift R, Ehara T, Yanagida H, Horton S, Noncovich A, et al. Peptide binder to Glypican-3 as a theranostic agent for hepatocellular carcinoma. J Nucl Med. 2024;65:586\u201392. https:\/\/doi.org\/10.2967\/jnumed.123.266766.","journal-title":"J Nucl Med"},{"key":"1396_CR50","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1042\/CS20220581","volume":"136","author":"X Wang","year":"2022","unstructured":"Wang X, Li Y, Pan M, Lu T, Wang M, Wang Z, et al. CEACAM5 inhibits the lymphatic metastasis of head and neck squamous cell carcinoma by regulating epithelial\u2013mesenchymal transition via inhibiting MDM2. Clin Sci. 2022;136:1691\u2013710. https:\/\/doi.org\/10.1042\/CS20220581.","journal-title":"Clin Sci"},{"key":"1396_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00599-6","volume":"8","author":"A Ajkunic","year":"2024","unstructured":"Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, et al. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: expression landscape and molecular correlates. NPJ Precis Oncol. 2024;8:104. https:\/\/doi.org\/10.1038\/s41698-024-00599-6.","journal-title":"NPJ Precis Oncol"},{"key":"1396_CR52","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","volume":"35","author":"E Dotan","year":"2017","unstructured":"Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, et al. Phase I\/II trial of Labetuzumab Govitecan (Anti-CEACAM5\/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol. 2017;35:3338\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.73.9011.","journal-title":"J Clin Oncol"},{"key":"1396_CR53","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1038\/s41591-025-03843-z","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz S, Boni V, Kato K, Raghav KPS, Vieito M, Pallis A, et al. Precemtabart tocentecan, an anti-CEACAM5 antibody\u2013drug conjugate, in metastatic colorectal cancer: a phase 1 trial. Nat Med. 2025;31:3504\u201313. https:\/\/doi.org\/10.1038\/s41591-025-03843-z.","journal-title":"Nat Med"},{"key":"1396_CR54","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/2767-9764.CRC-23-0284","volume":"3","author":"J Tabernero","year":"2023","unstructured":"Tabernero J, Bedard PL, Bang Y-J, Vieito M, Ryu M-H, Fagniez N, et al. Tusamitamab ravtansine in patients with advanced solid tumors: phase I study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens. Cancer Res Commun. 2023;3:1662\u201371. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0284.","journal-title":"Cancer Res Commun"},{"key":"1396_CR55","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2967\/jnumed.123.267107","volume":"65","author":"C Imberti","year":"2024","unstructured":"Imberti C, De Gregorio R, Korsen JA, Hoang TT, Khitrov S, Kalidindi T, et al. CEACAM5-targeted immuno-PET in Androgen Receptor\u2013Negative prostate cancer. J Nucl Med. 2024;65:1043\u201350. https:\/\/doi.org\/10.2967\/jnumed.123.267107.","journal-title":"J Nucl Med"},{"key":"1396_CR56","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.2967\/jnumed.122.264126","volume":"63","author":"M Minnix","year":"2022","unstructured":"Minnix M, Kujawski M, Poku E, Yazaki PJ, Wong JY, Shively JE. Improved tumor responses with sequential targeted \u03b1-particles followed by interleukin 2 immunocytokine therapies in treatment of CEA-positive breast and colon tumors in CEA transgenic mice. J Nucl Med. 2022;63:1859\u201364. https:\/\/doi.org\/10.2967\/jnumed.122.264126.","journal-title":"J Nucl Med"},{"key":"1396_CR57","doi-asserted-by":"publisher","unstructured":"Konopelski Snavely SE, Srinivasan S, Dreyer CA, Tan J, Carraway KL, Ho H-YH. Non-canonical WNT5A-ROR signaling: New perspectives on an ancient developmental pathway. 2023. pp. 195\u2013227. https:\/\/doi.org\/10.1016\/bs.ctdb.2023.01.009","DOI":"10.1016\/bs.ctdb.2023.01.009"},{"key":"1396_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110588","volume":"104","author":"MJ Quezada","year":"2023","unstructured":"Quezada MJ, Lopez-Bergami P. The signaling pathways activated by ROR1 in cancer. Cell Signal. 2023;104:110588. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110588.","journal-title":"Cell Signal"},{"key":"1396_CR59","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/0008-5472.CAN-21-1807","volume":"82","author":"F Ma","year":"2022","unstructured":"Ma F, Arai S, Wang K, Calagua C, Yuan AR, Poluben L, et al. Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer. Cancer Res. 2022;82:1518\u201333. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1807.","journal-title":"Cancer Res"},{"key":"1396_CR60","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1038\/s41388-018-0670-9","volume":"38","author":"H Karvonen","year":"2019","unstructured":"Karvonen H, Perttil\u00e4 R, Niininen W, Hautanen V, Barker H, Murum\u00e4gi A, et al. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. Oncogene. 2019;38:3288\u2013300. https:\/\/doi.org\/10.1038\/s41388-018-0670-9.","journal-title":"Oncogene"},{"key":"1396_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010142","volume":"10","author":"K Menck","year":"2021","unstructured":"Menck K, Heinrichs S, Baden C, Bleckmann A. The WNT\/ROR pathway in cancer: from signaling to therapeutic intervention. Cells. 2021;10:142. https:\/\/doi.org\/10.3390\/cells10010142.","journal-title":"Cells"},{"key":"1396_CR62","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.1200\/JCO.2021.39.15_suppl.7556","volume":"39","author":"HJ Lee","year":"2021","unstructured":"Lee HJ, Choi MY, Siddiqi T, Barrientos JC, Wierda WG, Isufi I, et al. Phase 1\/2 study of Cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). J Clin Oncol. 2021;39:7556\u20137556. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.7556.","journal-title":"J Clin Oncol"},{"key":"1396_CR63","doi-asserted-by":"publisher","unstructured":"Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, et al. Zilovertamab Vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid. 2022;1. https:\/\/doi.org\/10.1056\/EVIDoa2100001.","DOI":"10.1056\/EVIDoa2100001"},{"key":"1396_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01143-w","volume":"14","author":"VC Jiang","year":"2021","unstructured":"Jiang VC, Liu Y, Jordan A, McIntosh J, Li Y, Che Y, et al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021;14:132. https:\/\/doi.org\/10.1186\/s13045-021-01143-w.","journal-title":"J Hematol Oncol"},{"key":"1396_CR65","doi-asserted-by":"publisher","first-page":"TPS1108","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1108","volume":"39","author":"AW Tolcher","year":"2021","unstructured":"Tolcher AW, Meric-Bernstam F, McKean M, Beerli RR, Waldmeier L, Gebleux R, et al. NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors\u2014A phase 1\/2 clinical trial. J Clin Oncol. 2021;39:TPS1108\u20131108. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS1108.","journal-title":"J Clin Oncol"},{"key":"1396_CR66","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2024.42.16_suppl.3023","volume":"42","author":"CR Lemech","year":"2024","unstructured":"Lemech CR, Zuniga R, Barve MA, Song Y, Zhang J, Zhou K, et al. A phase 1a\/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2024;42:3023\u20133023. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3023.","journal-title":"J Clin Oncol"},{"key":"1396_CR67","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1038\/s41388-022-02416-5","volume":"41","author":"H Peng","year":"2022","unstructured":"Peng H, Nerreter T, Mestermann K, Wachter J, Chang J, Hudecek M, et al. ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene. 2022;41:4104\u201314. https:\/\/doi.org\/10.1038\/s41388-022-02416-5.","journal-title":"Oncogene"},{"key":"1396_CR68","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","volume":"31","author":"CA Jaeger-Ruckstuhl","year":"2025","unstructured":"Jaeger-Ruckstuhl CA, Specht JM, Voutsinas JM, MacMillan HR, Wu Q, Muhunthan V, et al. Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies. Clin Cancer Res. 2025;31:503\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2172.","journal-title":"Clin Cancer Res"},{"key":"1396_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02005-w","volume":"27","author":"F Wang","year":"2025","unstructured":"Wang F, Li W, Han G, Xie J, Bai X. A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer. Breast Cancer Res. 2025;27:47. https:\/\/doi.org\/10.1186\/s13058-025-02005-w.","journal-title":"Breast Cancer Res"},{"key":"1396_CR70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2019.05.016","volume":"458","author":"X Liu","year":"2019","unstructured":"Liu X, Pu W, He H, Fan X, Zheng Y, Zhou J-K, et al. Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer. Cancer Lett. 2019;458:76\u201385. https:\/\/doi.org\/10.1016\/j.canlet.2019.05.016.","journal-title":"Cancer Lett"},{"key":"1396_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102238","volume":"14","author":"A Ghaderi","year":"2022","unstructured":"Ghaderi A, Zhong W, Okhovat MA, Aschan J, Svensson A, Sander B, et al. A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of mantle cell lymphoma (MCL) cells. Pharmaceutics. 2022;14:2238. https:\/\/doi.org\/10.3390\/pharmaceutics14102238.","journal-title":"Pharmaceutics"},{"key":"1396_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198038","volume":"13","author":"AH Daneshmanesh","year":"2018","unstructured":"Daneshmanesh AH, Hojjat-Farsangi M, Ghaderi A, Moshfegh A, Hansson L, Schultz J, et al. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. PLoS One. 2018;13:e0198038. https:\/\/doi.org\/10.1371\/journal.pone.0198038.","journal-title":"PLoS One"},{"key":"1396_CR73","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1038\/s41375-018-0113-1","volume":"32","author":"M Hojjat-Farsangi","year":"2018","unstructured":"Hojjat-Farsangi M, Daneshmanesh AH, Khan AS, Shetye J, Mozaffari F, Kharaziha P, et al. First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Leukemia. 2018;32:2291\u20135. https:\/\/doi.org\/10.1038\/s41375-018-0113-1.","journal-title":"Leukemia"},{"key":"1396_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000928","volume":"8","author":"F Cappuccini","year":"2020","unstructured":"Cappuccini F, Bryant R, Pollock E, Carter L, Verrill C, Hollidge J, et al. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. J Immunother Cancer. 2020;8:e000928. https:\/\/doi.org\/10.1136\/jitc-2020-000928.","journal-title":"J Immunother Cancer"},{"key":"1396_CR75","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1158\/2326-6066.CIR-14-0079","volume":"3","author":"J Salimu","year":"2015","unstructured":"Salimu J, Spary LK, Al-Taei S, Clayton A, Mason MD, Staffurth J, et al. Cross-presentation of the oncofetal tumor antigen 5T4 from irradiated prostate cancer cells\u2014a key role for heat-shock protein 70 and receptor CD91. Cancer Immunol Res. 2015;3:678\u201388. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0079.","journal-title":"Cancer Immunol Res"},{"key":"1396_CR76","doi-asserted-by":"publisher","first-page":"47474","DOI":"10.18632\/oncotarget.17666","volume":"8","author":"F Cappuccini","year":"2017","unstructured":"Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy. Oncotarget. 2017;8:47474\u201389. https:\/\/doi.org\/10.18632\/oncotarget.17666.","journal-title":"Oncotarget"},{"key":"1396_CR77","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/sj.bjc.6602776","volume":"93","author":"RW Griffiths","year":"2005","unstructured":"Griffiths RW, Gilham DE, Dangoor A, Ramani V, Clarke NW, Stern PL, et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer. 2005;93:670\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6602776.","journal-title":"Br J Cancer"},{"key":"1396_CR78","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.lungcan.2012.03.008","volume":"77","author":"S Al-Taei","year":"2012","unstructured":"Al-Taei S, Salimu J, Lester JF, Linnane S, Goonewardena M, Harrop R, et al. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma. Lung Cancer. 2012;77:312\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2012.03.008.","journal-title":"Lung Cancer"},{"key":"1396_CR79","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/(SICI)1097-0215(19960927)68:1<84::AID-IJC15>3.0.CO;2-6","volume":"68","author":"CJ Carsberg","year":"1996","unstructured":"Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer. 1996;68:84\u201392.","journal-title":"Int J Cancer"},{"key":"1396_CR80","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1242\/jcs.108.8.2905","volume":"108","author":"CJ Carsberg","year":"1995","unstructured":"Carsberg CJ, Myers KA, Evans GS, Allen TD, Stern PL. Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane. J Cell Sci. 1995;108:2905\u201316. https:\/\/doi.org\/10.1242\/jcs.108.8.2905.","journal-title":"J Cell Sci"},{"key":"1396_CR81","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.yexcr.2018.02.001","volume":"364","author":"M Puchert","year":"2018","unstructured":"Puchert M, Koch C, Engele J. The 5T4 oncofetal glycoprotein does not act as a general organizer of the CXCL12 system in cancer cells. Exp Cell Res. 2018;364:175\u201383. https:\/\/doi.org\/10.1016\/j.yexcr.2018.02.001.","journal-title":"Exp Cell Res"},{"key":"1396_CR82","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1158\/1078-0432.CCR-22-1305","volume":"29","author":"JM Sperger","year":"2023","unstructured":"Sperger JM, Helzer KT, Stahlfeld CN, Jiang D, Singh A, Kaufmann KR, et al. Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer. Clin Cancer Res. 2023;29:2324\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1305.","journal-title":"Clin Cancer Res"},{"key":"1396_CR83","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989\u20139006. https:\/\/doi.org\/10.18632\/oncotarget.25615.","journal-title":"Oncotarget"},{"key":"1396_CR84","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1158\/0008-5472.CAN-12-3266","volume":"73","author":"M Trerotola","year":"2013","unstructured":"Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A, Languino LR. Trop-2 promotes prostate cancer metastasis by modulating \u03b21 integrin functions. Cancer Res. 2013;73:3155\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3266.","journal-title":"Cancer Res"},{"key":"1396_CR85","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00259-013-2434-7","volume":"40","author":"CM van Rij","year":"2013","unstructured":"van Rij CM, L\u00fctje S, Frielink C, Sharkey RM, Goldenberg DM, Franssen GM, et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging. 2013;40:1377\u201383. https:\/\/doi.org\/10.1007\/s00259-013-2434-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1396_CR86","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-621","volume":"10","author":"E Guerra","year":"2022","unstructured":"Guerra E, Alberti S. The anti-Trop-2 antibody-drug conjugate sacituzumab govitecan\u2014effectiveness, pitfalls and promises. Ann Transl Med. 2022;10:501. https:\/\/doi.org\/10.21037\/atm-22-621.","journal-title":"Ann Transl Med"},{"key":"1396_CR87","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.2217\/fon-2022-0407","volume":"18","author":"J Furlanetto","year":"2022","unstructured":"Furlanetto J, Marm\u00e9 F, Loibl S. Sacituzumab govitecan: past, present and future of a new antibody\u2013drug conjugate and future horizon. Future Oncol. 2022;18:3199\u2013215. https:\/\/doi.org\/10.2217\/fon-2022-0407.","journal-title":"Future Oncol"},{"key":"1396_CR88","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"1396_CR89","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fl\u00e9chon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39:2474\u201385. https:\/\/doi.org\/10.1200\/JCO.20.03489.","journal-title":"J Clin Oncol"},{"key":"1396_CR90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2094","volume":"42","author":"W Kelly","year":"2024","unstructured":"Kelly W, Cordova C, Vaillant BD, Balinda H, Michalek J, Gilbert A, et al. A phase II, multicenter, prospective study of sacituzumab govitecan in recurrent glioblastoma. J Clin Oncol. 2024;42:TPS2094. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS2094.","journal-title":"J Clin Oncol"},{"key":"1396_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50558-9","volume":"15","author":"HU Balinda","year":"2024","unstructured":"Balinda HU, Kelly WJ, Kaklamani VG, Lathrop KI, Canola MM, Ghamasaee P, et al. Sacituzumab govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial. Nat Commun. 2024;15:6707. https:\/\/doi.org\/10.1038\/s41467-024-50558-9.","journal-title":"Nat Commun"},{"key":"1396_CR92","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3098","author":"EC Pratt","year":"2025","unstructured":"Pratt EC, Mandleywala K, Bauer D, Bolaender A, Chao G, Castanares MA, et al. Pretargeted Trop-2 immunoPET for rapid, selective detection of pancreatic tumors. Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3098.","journal-title":"Clin Cancer Res"},{"key":"1396_CR93","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241269676","author":"X Fei","year":"2024","unstructured":"Fei X, Xue J-W, Wu J, Yang C-Y, Wang K-J, Ma Q. Promising therapy for neuroendocrine prostate cancer: current status and future directions. Ther Adv Med Oncol. 2024. https:\/\/doi.org\/10.1177\/17588359241269676.","journal-title":"Ther Adv Med Oncol"},{"key":"1396_CR94","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399. https:\/\/doi.org\/10.1146\/annurev-med-051517-011947.","journal-title":"Annu Rev Med"},{"key":"1396_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00708","author":"A Kolluri","year":"2019","unstructured":"Kolluri A, Ho M. The role of glypican-3 in regulating Wnt, YAP, and hedgehog in liver cancer. Front Oncol. 2019. https:\/\/doi.org\/10.3389\/fonc.2019.00708.","journal-title":"Front Oncol"},{"key":"1396_CR96","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/hep.22202","volume":"47","author":"J Lai","year":"2008","unstructured":"Lai J, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma\u2020. Hepatology. 2008;47:1211\u201322. https:\/\/doi.org\/10.1002\/hep.22202.","journal-title":"Hepatology"},{"key":"1396_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/cells8040370","volume":"8","author":"O Salem","year":"2019","unstructured":"Salem O, Hansen CG. The Hippo pathway in prostate cancer. Cells. 2019;8:370. https:\/\/doi.org\/10.3390\/cells8040370.","journal-title":"Cells"},{"key":"1396_CR98","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.62347\/TTNY4279","volume":"14","author":"J-Y Chung","year":"2024","unstructured":"Chung J-Y. Glypican-3 deficiency in liver cancer upregulates MAPK\/ERK pathway but decreases cell proliferation. Am J Cancer Res. 2024;14:3348\u201371. https:\/\/doi.org\/10.62347\/TTNY4279.","journal-title":"Am J Cancer Res"},{"key":"1396_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071570","volume":"13","author":"L Filippi","year":"2025","unstructured":"Filippi L, Frantellizzi V, Urso L, De Vincentis G, Urbano N. Targeting Glypican-3 in liver cancer: groundbreaking preclinical and clinical insights. Biomedicines. 2025;13:1570. https:\/\/doi.org\/10.3390\/biomedicines13071570.","journal-title":"Biomedicines"},{"key":"1396_CR100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1856","author":"Z Lin","year":"2025","unstructured":"Lin Z, Li M, Pan Z, Hu W, Feng Y, Zhang X, et al. Glypican-3\u2013targeted PET imaging for precise diagnosis of hepatocellular carcinoma: from bench to bedside. Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1856.","journal-title":"Clin Cancer Res"},{"key":"1396_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.preme.2025.100032","volume":"2","author":"D Li","year":"2025","unstructured":"Li D, Liu Y, Yang Z, Li N, Zhu H. Recent advances of nuclear medicine for tumor precision medicine. Precis Med Eng. 2025;2:100032. https:\/\/doi.org\/10.1016\/j.preme.2025.100032.","journal-title":"Precis Med Eng"},{"key":"1396_CR102","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.3390\/ijms26146815","volume":"26","author":"Y Nsereko","year":"2025","unstructured":"Nsereko Y, Armstrong A, Coburn F, Al Musaimi O. Innovative peptide therapeutics in the pipeline: transforming cancer detection and treatment. Int J Mol Sci. 2025;26:6815. https:\/\/doi.org\/10.3390\/ijms26146815.","journal-title":"Int J Mol Sci"},{"key":"1396_CR103","unstructured":"Li Z, Huang Y, Liang Y. GPC3-targeting PET molecular probe in preclinical diagnosis of hepatocellular carcinoma. J Nucl Med. 2024.65 (supplement 2) 241839."},{"key":"1396_CR104","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2967\/jnumed.124.268147","volume":"65","author":"AJ Poot","year":"2024","unstructured":"Poot AJ, Lapa C, Weber WA, Lam MGEH, Eiber M, Dierks A, et al. [ 68 Ga]Ga-RAYZ-8009: A Glypican-3\u2013Targeted diagnostic radiopharmaceutical for hepatocellular carcinoma molecular Imaging\u2014A First-in-Human case series. J Nucl Med. 2024;65:1597\u2013603. https:\/\/doi.org\/10.2967\/jnumed.124.268147.","journal-title":"J Nucl Med"},{"key":"1396_CR105","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2024.42.16_suppl.4019","volume":"42","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Fu Q, Cao W, Wang H, Xu X, Huang J, et al. Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2024;42:4019\u20134019. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4019.","journal-title":"J Clin Oncol"},{"key":"1396_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-2","volume":"7","author":"RD Blumenthal","year":"2007","unstructured":"Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer. 2007;7:2. https:\/\/doi.org\/10.1186\/1471-2407-7-2.","journal-title":"BMC Cancer"},{"key":"1396_CR107","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1084\/jem.121.3.439","volume":"121","author":"P Gold","year":"1965","unstructured":"Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439\u201362. https:\/\/doi.org\/10.1084\/jem.121.3.439.","journal-title":"J Exp Med"},{"key":"1396_CR108","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/1078-0432.CCR-20-3396","volume":"27","author":"DC DeLucia","year":"2021","unstructured":"DeLucia DC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, et al. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5\u2013SN38 antibody\u2013drug conjugate in neuroendocrine prostate cancer. Clin Cancer Res. 2021;27:759\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3396.","journal-title":"Clin Cancer Res"},{"key":"1396_CR109","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1021\/bc700161p","volume":"19","author":"L Li","year":"2008","unstructured":"Li L, Bading J, Yazaki PJ, Ahuja AH, Crow D, Colcher D, et al. A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. Bioconjug Chem. 2008;19:89\u201396. https:\/\/doi.org\/10.1021\/bc700161p.","journal-title":"Bioconjug Chem"},{"key":"1396_CR110","doi-asserted-by":"publisher","first-page":"603","DOI":"10.5306\/wjco.v15.i5.603","volume":"15","author":"Z-L Wu","year":"2024","unstructured":"Wu Z-L, Wang Y, Jia X-Y, Wang Y-G, Wang H. Receptor tyrosine kinase-like orphan receptor 1: a novel antitumor target in gastrointestinal cancers. World J Clin Oncol. 2024;15:603\u201313. https:\/\/doi.org\/10.5306\/wjco.v15.i5.603.","journal-title":"World J Clin Oncol"},{"key":"1396_CR111","doi-asserted-by":"publisher","first-page":"26181","DOI":"10.1016\/S0021-9258(18)35733-8","volume":"267","author":"P Masiakowski","year":"1992","unstructured":"Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem. 1992;267:26181\u201390.","journal-title":"J Biol Chem"},{"key":"1396_CR112","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.9500","author":"G Xu","year":"2018","unstructured":"Xu G, Shen J, Xu Y, Wang W, Ni C. ROR1 is highly expressed in circulating tumor cells and promotes invasion of pancreatic cancer. Mol Med Rep. 2018. https:\/\/doi.org\/10.3892\/mmr.2018.9500.","journal-title":"Mol Med Rep"},{"key":"1396_CR113","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/ijc.23587","volume":"123","author":"AH DaneshManesh","year":"2008","unstructured":"DaneshManesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008;123:1190\u20135. https:\/\/doi.org\/10.1002\/ijc.23587.","journal-title":"Int J Cancer"},{"key":"1396_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127092","volume":"10","author":"Y Liu","year":"2015","unstructured":"Liu Y, Yang H, Chen T, Luo Y, Xu Z, Li Y, et al. Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K\/AKT\/mTOR signaling pathway in lung adenocarcinoma. PLoS One. 2015;10:e0127092. https:\/\/doi.org\/10.1371\/journal.pone.0127092.","journal-title":"PLoS One"},{"key":"1396_CR115","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.37349\/etat.2023.00192","volume":"4","author":"V Sivaganesh","year":"2023","unstructured":"Sivaganesh V, Peethambaran B. Receptor tyrosine kinase-like orphan receptor 1 inhibitor Strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer. Explor Target Antitumor Ther. 2023;4:1188\u2013209. https:\/\/doi.org\/10.37349\/etat.2023.00192.","journal-title":"Explor Target Antitumor Ther"},{"key":"1396_CR116","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","volume":"181","author":"S Zhang","year":"2012","unstructured":"Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012;181:1903\u201310. https:\/\/doi.org\/10.1016\/j.ajpath.2012.08.024.","journal-title":"Am J Pathol"},{"key":"1396_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02239-1","volume":"10","author":"A-B Tigu","year":"2024","unstructured":"Tigu A-B, Munteanu R, Moldovan C, Rares D, Kegyes D, Tomai R, et al. Therapeutic advances in the targeting of ROR1 in hematological cancers. Cell Death Discov. 2024;10:471. https:\/\/doi.org\/10.1038\/s41420-024-02239-1.","journal-title":"Cell Death Discov"},{"key":"1396_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137003","volume":"25","author":"V Sivaganesh","year":"2024","unstructured":"Sivaganesh V, Ta TM, Peethambaran B. Pentagalloyl glucose (PGG) exhibits anti-cancer activity against aggressive prostate cancer by modulating the ROR1 mediated AKT-GSK3\u03b2 pathway. Int J Mol Sci. 2024;25:7003. https:\/\/doi.org\/10.3390\/ijms25137003.","journal-title":"Int J Mol Sci"},{"key":"1396_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.680834","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhang D, Guo Y, Lu B, Zhao ZJ, Xu X, et al. Tyrosine kinase ROR1 as a target for anti-cancer therapies. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.680834.","journal-title":"Front Oncol"},{"key":"1396_CR120","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1182\/bloodadvances.2020003276","volume":"5","author":"EY Hu","year":"2021","unstructured":"Hu EY, Do P, Goswami S, Nunes J, Chiang C, Elgamal S, et al. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1\u2009+\u2009leukemia. Blood Adv. 2021;5:3152\u201362. https:\/\/doi.org\/10.1182\/bloodadvances.2020003276.","journal-title":"Blood Adv"},{"key":"1396_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041148","volume":"15","author":"A Ghaderi","year":"2023","unstructured":"Ghaderi A, Okhovat M-A, Lehto J, De Petris L, Manouchehri Doulabi E, Kokhaei P, et al. A small molecule targeting the intracellular tyrosine kinase domain of ROR1 (KAN0441571C) induced significant apoptosis of non-small cell lung cancer (NSCLC) cells. Pharmaceutics. 2023;15:1148. https:\/\/doi.org\/10.3390\/pharmaceutics15041148.","journal-title":"Pharmaceutics"},{"key":"1396_CR122","unstructured":"Artschwager R, Luo A, Mun JS, Kalidindi T. Daniel Okpattah, Naga vara Kishore Pillarsetty. Targeting ROR1 for the imaging of triple negative breast cancer. J Nucl Med. 2024.65 (supplement 2) 242236."},{"key":"1396_CR123","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162907","author":"E Sayar","year":"2023","unstructured":"Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023. https:\/\/doi.org\/10.1172\/jci.insight.162907.","journal-title":"JCI Insight"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01396-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01396-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01396-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:50:27Z","timestamp":1776898227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01396-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1396"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01396-x","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OS reports consulting activities with Abdera, Actithera, AdvanCell, Alpha9, Amgen, ARTbio, Astellas, AstraZeneca, Bayer, Clarity Pharmaceuticals, Convergent, Curadh, Fusion, ITM Oncologics, Janssen (JNJ), Lantheus, Merck, Norroy, NorthStar, Novartis, Nucleus Biopharma, Pfizer, RATIO, Sanofi, Swiss Rockets, and Telix. He holds stock or options in Abdera, Actithera, AdvanCell, ArtBio, Clarity, Convergent, Ratio, and Telix. He has received clinical trial support to his institution from Amgen, AstraZeneca, Bayer, Janssen, and Novartis. FL discloses research funding and financial compensation from NaNotics LLC, a licensing agreement and royalties from Early is Good, and consulting for Mursla Bio. DSC reports honoraria, advisory board participation, or supported travel from Janssen (to institution), Novartis (to institution), Abdera (to institution), DAVA Oncology, Curio, Targeted Oncology, MJH Life Sciences, GU Oncology Now, IDEOlogy, IntrinsiQ, the American Society of Clinical Oncology, the Prostate Cancer Foundation, and the International Centers for Precision Oncology. He has received research funding from Janssen (to institution) and Novartis (to institution, in progress). ATK reports consulting for Novartis Inc. and research grant support to her institution from Novartis Inc. JJO receives research support from the Prostate Cancer Foundation (YIA), Department of Defense, and National Cancer Institute (K12 CA90628-23). JJO previously received research support from Nanotics, Genentech, and Partner Therapeutics. JJO reports support and\/or research and consulting support from the Prostate Cancer Foundation, NaNotics, Genentech, and Partner Therapeutics. The other authors have no financial or non-financial conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}